Tier 3 — preclinical

Bioavailability of resveratrol

Walle T
Annals of the New York Academy of Sciences 2011 1215:9-15

Bibliography

PubMed
PMID 21261636
DOI
10.1111/j.1749-6632.2010.05842.x
Funding
Not stated in the available abstract.
Competing interests
Not stated in the available abstract.

Study snapshot

DesignNarrative review
ModelHuman (review of existing human absorption, distribution, metabolism data)
SampleNot applicable (review)
InterventionNot applicable (review of existing resveratrol dosing/absorption literature)
DurationNot applicable (review)
EndpointsOral absorption fraction; Oral bioavailability of parent resveratrol; Major circulating metabolite profile (glucuronides and sulfates)

What the study showed, in plain terms

This review explains why so little resveratrol actually reaches the bloodstream in its active form. Around 75% of an oral dose is absorbed across the gut wall, but the liver and intestine rapidly convert almost all of it into glucuronide and sulfate metabolites, leaving well under 1% as the active parent compound. Taking a higher or repeated dose does not meaningfully change this pattern.

Key findings

Oral absorption of resveratrol in humans is approximately 75%, occurring mainly via passive transepithelial diffusion. Extensive first-pass metabolism in the intestine and liver converts most of the absorbed dose to glucuronide and sulfate conjugates, so the oral bioavailability of unmetabolised resveratrol is considerably less than 1%. Dose escalation and repeated dosing do not appear to meaningfully change this. Colonic bacterial metabolism may play a larger role in resveratrol disposition than previously recognised.

What this study can and cannot tell us

This is a narrative review, not a systematic review or a new experimental study, so it synthesises existing pharmacokinetic data rather than generating new controlled comparisons. It predates and does not evaluate newer bioavailability-enhancing formulations such as phytosome, liposomal, or piperine-combination resveratrol products.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability